CINECA IRIS Institutional Research Information System

MARINO', MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.991
AS - Asia 6.803
EU - Europa 5.478
SA - Sud America 1.106
AF - Africa 342
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 6
Totale 28.734
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.604
SG - Singapore 2.215
CN - Cina 1.734
IT - Italia 1.685
HK - Hong Kong 1.229
SE - Svezia 1.019
BR - Brasile 892
VN - Vietnam 610
DE - Germania 608
BG - Bulgaria 443
GB - Regno Unito 372
FR - Francia 346
CA - Canada 287
TR - Turchia 240
RU - Federazione Russa 217
FI - Finlandia 200
IN - India 178
UA - Ucraina 145
AT - Austria 143
CI - Costa d'Avorio 114
KR - Corea 92
JP - Giappone 83
BD - Bangladesh 78
SN - Senegal 63
IQ - Iraq 61
AR - Argentina 54
CH - Svizzera 53
ZA - Sudafrica 52
NL - Olanda 49
SA - Arabia Saudita 44
MX - Messico 43
EC - Ecuador 37
PL - Polonia 36
BE - Belgio 31
PK - Pakistan 31
VE - Venezuela 30
CO - Colombia 27
ES - Italia 27
UZ - Uzbekistan 26
ID - Indonesia 25
MA - Marocco 23
DZ - Algeria 19
IE - Irlanda 17
NP - Nepal 15
PE - Perù 15
PH - Filippine 15
PY - Paraguay 15
AZ - Azerbaigian 14
CL - Cile 14
AE - Emirati Arabi Uniti 13
EG - Egitto 13
JO - Giordania 13
MY - Malesia 13
CZ - Repubblica Ceca 12
GR - Grecia 12
KE - Kenya 11
UY - Uruguay 11
LT - Lituania 10
NG - Nigeria 10
CR - Costa Rica 9
HU - Ungheria 9
JM - Giamaica 9
AU - Australia 8
RO - Romania 8
TN - Tunisia 8
BJ - Benin 7
BO - Bolivia 7
ET - Etiopia 7
GE - Georgia 7
LB - Libano 7
TT - Trinidad e Tobago 7
BB - Barbados 6
DO - Repubblica Dominicana 6
IL - Israele 6
KG - Kirghizistan 6
PA - Panama 6
RS - Serbia 6
TW - Taiwan 6
IR - Iran 5
KZ - Kazakistan 5
PS - Palestinian Territory 5
TH - Thailandia 5
AL - Albania 4
BH - Bahrain 4
EU - Europa 4
HR - Croazia 4
OM - Oman 4
PT - Portogallo 4
CG - Congo 3
EE - Estonia 3
GT - Guatemala 3
MD - Moldavia 3
NO - Norvegia 3
SK - Slovacchia (Repubblica Slovacca) 3
SR - Suriname 3
SY - Repubblica araba siriana 3
BS - Bahamas 2
DK - Danimarca 2
KH - Cambogia 2
KW - Kuwait 2
Totale 28.699
Salva come PNG Salva come JPEG
Città #
Ashburn 1.526
Woodbridge 1.460
Fairfield 1.218
Hong Kong 1.211
Singapore 1.179
Ann Arbor 1.058
Houston 971
Dallas 969
San Jose 813
Santa Clara 800
Chandler 703
Seattle 505
Milan 446
Sofia 441
Shanghai 414
Beijing 402
Wilmington 387
Cambridge 380
New York 334
Serra 248
Ottawa 228
Los Angeles 219
Boardman 209
Princeton 186
Lawrence 173
Ho Chi Minh City 160
Jacksonville 155
Munich 154
Medford 148
Lauterbourg 144
London 136
Vienna 127
Florence 120
Izmir 116
Abidjan 114
Hefei 109
Hanoi 102
Nanjing 97
Dong Ket 94
Seoul 89
Des Moines 86
Istanbul 81
Buffalo 79
Bremen 75
Frankfurt am Main 75
Dearborn 73
Redondo Beach 72
Tokyo 68
Rome 67
São Paulo 64
San Diego 63
Marseille 62
Dakar 61
Nanchang 59
Pisa 56
Turku 55
Ogden 49
Bern 44
Chicago 40
Orem 39
Council Bluffs 36
Jüchen 36
Düsseldorf 35
Lancaster 35
Redwood City 35
Brussels 31
Rio de Janeiro 31
Atlanta 30
Kunming 30
Baghdad 29
Helsinki 29
Hebei 28
Columbus 25
Norwalk 25
Brooklyn 23
Da Nang 23
Denver 23
Tashkent 23
Warsaw 23
Chennai 21
Johannesburg 21
Shenyang 21
Changsha 20
Fuzhou 20
Guangzhou 20
Montreal 20
Poplar 20
Vicopisano 20
Boulder 19
Brasília 19
Jiaxing 19
San Francisco 19
The Dalles 19
Jeddah 18
Paris 18
Phoenix 18
Nuremberg 17
Washington 17
Dhaka 16
Lucca 16
Totale 20.561
Salva come PNG Salva come JPEG
Nome #
Complicanze chirurgiche in pazienti sottoposti a decompressione orbitaria per oftalmopatia di Graves [Surgical complications in orbital decompression for Graves’ orbitopathy] 454
Thyroid directed antibodies 366
Natural history of graves’ orbitopathy after treatment 265
Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy 243
Sortilin is a putative post-endocytic receptor of thyroglobulin 223
Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment? 222
Role of the underlying thyroid disease on the phenotype of graves' orbitopathy in a tertiary referral center 219
False negative results observed in anti-thyroid peroxidase autoantibody determination by competitive radioimmunoassays using monoclonal antibodies 218
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study 214
Targeting of thyroglobulin to transcytosis following megalin-mediated endocytosis: evidence for a preferential ph-independent pathway 204
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 203
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 201
Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts 200
TSH-Dependent Expression of the LDL Receptor-Associated Protein (RAP) in Thyroid Epithelial Cells 197
TSH-Dependent expression of the LDL receptor-associated protein (RAP) in thyroid epithelial cells 193
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial 193
Effect of thyroglobulin autoantibodies on the metabolic clearance of serum thyroglobulin 193
Sequencing of the entire coding region of the receptor associated protein (RAP) in patients with primary hypothyroidism of unknown origin 190
Significance of low levels of thyroglobulin autoantibodies associated with undetectable thyroglobulin after thyroidectomy for differentiated thyroid carcinoma 190
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study 190
Outcome of Graves' Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial 188
Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: An example of selective anti-TSH-receptor immune response 188
Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO) 187
Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement 187
Thyroglobulin Autoantibodies arise before Thyroperoxidase Autoantibodies in Juvenile Autoimmune Thyroiditis 187
Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases 185
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with graves’ ophthalmopathy 184
VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY 184
Spontaneous improvement of untreated mild graves' ophthalmopathy: Rundle's curve revisited. 183
Circulating thyroglobulin transcytosed by thyroid cells is complexed with secretory components of its endocytic receptor megalin 181
Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy 177
Serum antibodies against megalin (gp330) in patients with autoimmune thyroiditis 176
Occurrence of Graves’ Orbitopathy and of Graves’ hyperthyroidism after a trauma to the eye 176
Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: the hypothesis of Kriss revisited 175
Effect of thyroglobulin autoantibodies on the clearance of serum thyroglobulin in humans 175
Binding of thyroglobulin (Tg) to the low-density lipoprotein receptor-associated protein (RAP) during the biosynthetic pathway prevents premature Tg interactions with sortilin 174
Dissecting the genetic susceptibility to graves' disease in a cohort of patients of Italian origin 174
Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves’ orbitopathy 173
A case of drug-induced Graves’ Orbitopathy after combination therapy with Tremelimumab and Durvalumab 173
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 173
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 173
Choroidal vascularity index in thyroid-associated ophthalmopathy: a cross-sectional study 172
Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study 172
Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma 171
A treatment strategy for Graves' orbitopathy 171
Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question 171
Orbit-Thyroid Relationship 170
Pathogenetic and clinical aspects of autoimmune thyroiditis 170
Glycosaminoglycans provide a binding site for thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy 170
Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' Orbitopathy 170
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 169
Impaired Thyroglobulin (Tg) Secretion By FRTL-5 Cells Transfected With Soluble Receptor Associated Protein (RAP): Evidence For A Role Of RAP In The Tg Biosynthetic Pathway 166
DEFECTIVE THYROGLOBULIN (Tg) STORAGE IN LDL RECEPTOR ASSOCIATED PROTEIN (RAP) DEFICIENT MICE 166
IgM thyroglobulin autoantibodies are detectable in serum of patients with subacute thyroiditis 164
In Graves' disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features 163
Role of thyroglobulin endocytic pathways in the control of thyroid hormone release 162
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 162
Selenium in the Treatment of Thyroid Diseases 161
Thyroid volume and severity of graves' orbitopathy 157
Outcome of Graves’ Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial 156
Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy 156
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 156
Cytokines in thyroid autoimmune infiltrate 155
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 155
Binding of the low density lipoprotein receptor associated protein (RAP) to thyroglobulin (Tg): putative role of RAP in the Tg secretory pathway 155
Rehabilitative orbital decompression for Graves’ orbitopathy: results of a randomized clinical trial 155
BINDING, UPTAKE AND DEGRADATION OF INTERNALIZED THYROGLOBULIN IN CULTURED THYROID AND NON THYROID CELLS 155
Megalin-mediated transcytosis of thyroglobulin by thyroid cells is a calmodulin-dependent process 154
Intracellular retention of thyroglobulin in the absence of the low-density lipoprotein receptor-associated protein (RAP) is likely due to premature binding to megalin in the biosynthetic pathway 154
Acute liver damage following intravenous glucocorticoid treatment for Graves’ ophthalmopathy 154
Megalin (gp330): a putative endocytic receptor for thyroglobulin (Tg) 153
Identification of a heparin-binding region of rat thyroglobulin involved in megalin binding 153
Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis 153
Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? 152
Binding of heparin to human thyroglobulin (Tg) involves multiple binding sites including a region corresponding to a binding site of rat Tg 152
Circulating thyroid autoantibodies in a sample of Italian octo-nonagenarians: relationship to age, sex, disability, and lipid profile 152
Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study 152
Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study 152
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 152
Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy 151
Prognostic factors 149
Kidney abnormalities in low density lipoprotein receptor associated protein knockout mice 148
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy 148
PREGO ( presentation of Graves' orbitopathy) study: Changes in referral patterns to European Group on Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012 148
Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves’ Orbitopathy – A randomized, observer blind, multicenter trial 148
Outcome of orbital decompression for disfiguring proptosis in patients with Graves' orbitopathy using various surgical procedures. 147
Thyroid dysfunction in megalin deficient mice 146
Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia Gravis 146
ABSENCE OF PRIMARY HYPOTHYROIDISM AND GOITER IN SLC26A4 (-/-) MICE FED ON A LOW IODINE DIET 145
Binding of rat thyroglobulin to heparan sulfate proteoglycans 145
Rehabilitative orbital decompression for Graves' orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients' satisfaction 145
Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. 144
Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases-Authors response. Letters to the Editor 143
Peripheral T and B lymphocytes do not correlate with Graves’ orbitopathy 143
Effects of total thyroid ablation vs near-total thyroidectomy alone on mild to moderate Graves' Orbitopathy treated with intravenous glucocorticoids 142
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 142
Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey 141
Retinal, choroidal and optic disc analysis in patients with Graves' disease with or without orbitopathy 140
A questionnaire survey on the management of Graves' orbitopathy in Europe 139
CIC-5 does not affect megalin expression and function in the thyroid 138
Totale 17.472
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.993
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021214 0 0 0 0 0 0 0 0 0 0 0 214
2021/20222.177 37 100 45 197 395 254 59 103 179 230 85 493
2022/20232.519 281 374 212 203 237 316 13 189 479 16 168 31
2023/20241.751 208 205 211 129 246 309 62 59 24 28 107 163
2024/20256.203 41 210 105 286 619 652 457 292 666 785 716 1.374
2025/20267.085 537 944 1.047 746 705 564 931 336 289 654 219 113
Totale 29.105